Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06290687 · ClinicalTrials.gov registry record · Phase 2
Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic Therapy
A Phase 2 study of Muscle-Invasive Bladder Carcinoma and Malignant Neoplasm of Bladder, sponsored by Case Comprehensive Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06290687 is a Phase 2 study of Muscle-Invasive Bladder Carcinoma and Malignant Neoplasm of Bladder that is actively recruiting participants, run by Case Comprehensive Cancer Center. The registered enrollment target is 40 participants, below the 123-participant average among 14 other Muscle-Invasive Bladder Carcinoma trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06290687, a Phase 2 study of Muscle-Invasive Bladder Carcinoma and Malignant Neoplasm of Bladder, is actively recruiting participants, sponsored by Case Comprehensive Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to determine if a partial cystectomy with extended pelvic lymph node removal will be effective at treating Muscle-Invasive Bladder Cancer instead of a complete cystectomy with extended pelvic lymph node removal. This clinical trial aims to determine the safety and oncologic efficacy of the intervention, and to examine patient-reported quality of life outcomes in participants. Participants will receive the standard pre-surgery treatment for approximately 4 to 6 weeks. After the pre-surgery treatment is completed, participants will undergo a partial cystectomy with extended pelvic lymph node dissection. After surgery, participants will receive adjuvant systemic therapy.
Conditions Studied
Interventions
- DRUG Neoadjuvant Chemotherapy
- PROCEDURE Partial cystectomy with Extended pelvic lymph node dissection
- DRUG Adjuvant systemic therapy
Study Locations (1)
Ohio
- Glickman Urological and Kidney Institute, Cleveland Clinic, Case Comprehensive Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-02-18 |
| Est. Completion | 2027-12-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06290687
The ClinicalTrials.gov registry entry for NCT06290687 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 123-participant average among 14 other Muscle-Invasive Bladder Carcinoma trials with a reported enrollment target (67% lower). The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Muscle-Invasive Bladder Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Neoadjuvant Chemotherapy is the first listed.
NCT06290687 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT06290687 about?
NCT06290687 is a clinical study titled "Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic Therapy". The goal of this clinical trial is to determine if a partial cystectomy with extended pelvic lymph node removal will be effective at treating Muscle-Invasive Bladder Cancer instead of a complete cystectomy with extended pelvic lymph node removal. This clinical trial aims to determine the safety and ...
What is the current status of trial NCT06290687?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-02-18. Estimated completion is 2027-12-29.
What conditions does trial NCT06290687 study?
This clinical trial studies the following conditions: Muscle-Invasive Bladder Carcinoma, Malignant Neoplasm of Bladder.
What interventions are being tested in trial NCT06290687?
The interventions under investigation include: Neoadjuvant Chemotherapy (DRUG), Partial cystectomy with Extended pelvic lymph node dissection (PROCEDURE), Adjuvant systemic therapy (DRUG).
Who is sponsoring clinical trial NCT06290687?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06290687 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Muscle-Invasive Bladder Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)
RECRUITING · Phase 2
-
Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology
RECRUITING · Phase 2
-
Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors
RECRUITING · Phase 2
-
Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy
RECRUITING · Phase 2
-
Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer
RECRUITING · Phase 2
-
A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.